Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.47−0.39 (-1.35%)
Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%
Pfizer gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Pfizer's gross profit for the twelve months ending Jun 28, 2026 was $46.61B, up 1.2% year over year. For fiscal 2025 it was $46.51B, up 1.6% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $66.83B in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.51B | +1.6% |
| FY2024 | Dec 31, 2024 | $45.78B | +32.3% |
| FY2023 | Dec 31, 2023 | $34.60B | -48.2% |
| FY2022 | Dec 31, 2022 | $66.83B | +32.4% |
| FY2021 | Dec 31, 2021 | $50.47B | +52.2% |
| FY2020 | Dec 31, 2020 | $33.17B | +1.0% |
| FY2019 | Dec 31, 2019 | $32.85B | +3.2% |
| FY2018 | Dec 31, 2018 | $31.84B | -22.9% |
| FY2017 | Dec 31, 2017 | $41.32B | +2.0% |
| FY2016 | Dec 31, 2016 | $40.50B | +3.3% |
| FY2015 | Dec 31, 2015 | $39.20B | -2.1% |
| FY2014 | Dec 31, 2014 | $40.03B | -4.7% |
| FY2013 | Dec 31, 2013 | $42.00B | -6.3% |
| FY2012 | Dec 31, 2012 | $44.84B | -7.6% |
| FY2011 | Dec 31, 2011 | $48.54B | -3.7% |
| FY2010 | Dec 31, 2010 | $50.38B | +23.4% |
| FY2009 | Dec 31, 2009 | $40.81B | +1.6% |
| FY2008 | Dec 31, 2008 | $40.18B | +8.1% |
| FY2007 | Dec 31, 2007 | $37.18B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 28, 2026 | $10.94B | +0.6% |
| Q1 FY2026 | Mar 29, 2026 | $10.90B | +0.3% |
| Q4 FY2025 | Dec 31, 2025 | $12.29B | +3.6% |
| Q3 FY2025 | Sep 28, 2025 | $12.48B | +0.3% |
| Q2 FY2025 | Jun 29, 2025 | $10.88B | +8.9% |
| Q1 FY2025 | Mar 30, 2025 | $10.87B | -5.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.85B | +69.2% |
| Q3 FY2024 | Sep 29, 2024 | $12.44B | +194.6% |
| Q2 FY2024 | Jun 30, 2024 | $9.98B | +2.2% |
| Q1 FY2024 | Mar 31, 2024 | $11.50B | -15.4% |
| Q4 FY2023 | Dec 31, 2023 | $7.01B | -54.8% |
| Q3 FY2023 | Oct 1, 2023 | $4.22B | -74.5% |
| Q2 FY2023 | Jul 2, 2023 | $9.77B | -48.8% |
| Q1 FY2023 | Apr 2, 2023 | $13.60B | -13.2% |
| Q4 FY2022 | Dec 31, 2022 | $15.49B | +9.8% |
| Q3 FY2022 | Oct 2, 2022 | $16.58B | +17.5% |
| Q2 FY2022 | Jul 3, 2022 | $19.09B | +60.4% |
| Q1 FY2022 | Apr 3, 2022 | $15.68B | +51.3% |
| Q4 FY2021 | Dec 31, 2021 | $14.10B | +61.8% |
| Q3 FY2021 | Oct 3, 2021 | $14.10B | +70.5% |
| Q2 FY2021 | Jul 4, 2021 | $11.90B | +48.1% |
| Q1 FY2021 | Apr 4, 2021 | $10.36B | +27.2% |
| Q4 FY2020 | Dec 31, 2020 | $8.72B | +522.6% |
| Q3 FY2020 | Sep 27, 2020 | $8.27B | -17.9% |
| Q2 FY2020 | Jun 28, 2020 | $8.04B | -24.8% |
| Q1 FY2020 | Mar 29, 2020 | $8.14B | -23.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.40B | +310.6% |
| Q3 FY2019 | Sep 29, 2019 | $10.08B | -5.0% |
| Q2 FY2019 | Jun 30, 2019 | $10.69B | +1.3% |
| Q1 FY2019 | Mar 31, 2019 | $10.69B | +3.3% |
| Q4 FY2018 | Dec 31, 2018 | $341.00M | -96.7% |
| Q3 FY2018 | Sep 30, 2018 | $10.60B | +2.7% |
| Q2 FY2018 | Jul 1, 2018 | $10.55B | +3.1% |
| Q1 FY2018 | Apr 1, 2018 | $10.34B | +0.3% |
| Q4 FY2017 | Dec 31, 2017 | $10.45B | +0.3% |
| Q3 FY2017 | Oct 1, 2017 | $10.32B | +3.7% |
| Q2 FY2017 | Jul 2, 2017 | $10.24B | – |
| Q1 FY2017 | Apr 2, 2017 | $10.31B | – |
| Q4 FY2016 | Dec 31, 2016 | $10.42B | – |
| Q3 FY2016 | Oct 2, 2016 | $9.96B | – |
See a number that looks wrong?